FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

OMB APPROVAL OMB Number: Estimated average burden hours per response: 0.5

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940

1. Name and Address of Reporting Person* <u>LEVIN ARTHUR A</u>							2. Issuer Name and Ticker or Trading Symbol ISIS PHARMACEUTICALS INC [ISIS]										onship of Reporting Pe all applicable) Director Officer (give title		on(s) to Issi 10% Ov Other (s	vner	
(Last) (First) (Middle) C/O ISIS PHARMACEUTICALS, INC. 1896 RUTHERFORD ROAD						3. Date of Earliest Transaction (Month/Day/Year) 04/25/2007										Vice President					
(Street) CARLSBAD CA 92008 (City) (State) (Zip)					-											i. Individual or Joint/Group Filing (Check Applicable ine) X Form filed by One Reporting Person Form filed by More than One Reporting Person					
		Tab	le I - No	n-Deri	vativ	e Se	curit	ies A	cqı	uired, I	Dis	posed o	f, or Be	nefic	ially	Owned					
Da				Date	2. Transaction Date (Month/Day/Year)			2A. Deemed Execution Date, if any (Month/Day/Year)			tion str.	4. Securities Acquired (A) Disposed Of (D) (Instr. 3, 4 5)			4 and Securitie Benefici Owned F		es ally Following	Form (D) o	n: Direct r Indirect istr. 4)	7. Nature of Indirect Beneficial Ownership	
											v	Amount	(A) or (D)	Pric	ce	Reported Transact (Instr. 3	tion(s)			(Instr. 4)	
Common Stock 04/25/						2007 04/25/2007			7	M ⁽¹⁾		6,000	l) A	\$	5.25	7,	674		D		
Common Stock 04/25/						/2007 04/25/200			7	S ⁽²⁾		6,000(2	2) D	\$1	0.11	1,	574		D		
		-	Гable II -									osed of, onvertil				Owned					
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deeme Execution if any (Month/Da	Date,	4. Transacti Code (Ins		5. Number of			Date Exer opiration D lonth/Day/	ate		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)] (B. Price of Derivative Security Instr. 5)	9. Numbe derivative Securities Beneficial Owned Following Reported Transactic (Instr. 4)	s Illy	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)	
					Code	v	(A)	(D)	Da Ex	ate kercisable		Expiration Date	Title	Amo or Num of Shar	ber						
Employee Stock Option (right to buy)	\$5.25	04/25/2007	04/25/2007		M			6,000	01	./03/2007 ⁽³	3)	01/02/2013	Common Stock	6,0	00	\$0	23,70	3	D		

Explanation of Responses:

- 1. The purchase reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 4/18/07.
- 2. The sale reported on this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on 4/18/07.
- 3. Stock option under the Isis Pharmaceuticals, Inc. 1989 Stock Option Plan. 25% of the shares subject to the option vested and became exercisable on 1/3/07. Thereafter, the remaining shares subject to the option vest and become exercisable in 36 equal monthly installments, at the rate of 7,426 shares per year. The option was exercisable as to 9,282 shares on 4/25/07 prior to the reported exercise.

Remarks:

/s/Arthur A. Levin

04/26/2007

** Signature of Reporting Person

Date

Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.

- * If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
- ** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).

Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.

Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.